YOLO Immune

YOLO Immune is a venture-backed biotechnology company focused on developing precision immunotherapies for serious human diseases, including ocular tumors, liver diseases, and autoimmune conditions. Founded in 2023 and based in San Carlos, California, the company utilizes a human-centric drug discovery platform to design targeted, multi-functional biologics. Its lead program, YOL104 (including YOL104-2), is a bioengineered, trivalent, multifunctional peptibody incorporating a core interferon-mimetic under investigation for the treatment of ocular surface squamous neoplasia (OSSN). In October 2026, YOLO Immune entered into an asset purchase option agreement with Visara, Inc. (a subsidiary of NovaBridge Biosciences) for the worldwide rights to the YOL104 program. Additionally, the company is developing a novel immunotherapy for the specific depletion of the IgG4 subtype of autoantibodies to treat autoimmune diseases, supported by a National Science Foundation (NSF) SBIR Phase I grant.